Pre-Exposure Prophylaxis: State of the Science (and Art)

Kenneth H. Mayer, M.D.
Fenway Health
Beth Israel Deaconess Medical Center
Harvard Medical School
Why Chemoprophylaxis Post-HPTN 052?

- Only few MSM and IDU in HPTN 052, so effectiveness of TasP not fully understood.
- HIV incidence has not ↓ in England and Denmark, despite access (Birrell, 2013; Audelin, 2013).
- <1/3rd of PLHIV globally are now on treatment; full access will take years.
- Not all PLHIV want to start meds with high CD4 counts, and virologic suppression rates vary.
- Serostatus awareness is limited among many.
- HIV stigma limits willingness to disclose.
- Not either/or; models suggest some synergy.
PrEP works, but adherence is critical

<table>
<thead>
<tr>
<th>Study</th>
<th>Efficacy overall</th>
<th>Drug detected overall</th>
<th>Estimated Risk reduction with drug detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>iPrEx</td>
<td>42%</td>
<td>~50%</td>
<td>92%</td>
</tr>
<tr>
<td>Partners PrEP</td>
<td>67-75%</td>
<td>82%</td>
<td>86% (TDF) 90% (FTC/TDF)</td>
</tr>
<tr>
<td>TDF-2</td>
<td>62%</td>
<td>80%</td>
<td>78%</td>
</tr>
<tr>
<td>Fem-PrEP</td>
<td>No efficacy</td>
<td>26%</td>
<td>“adherence too low to assess efficacy”</td>
</tr>
<tr>
<td>VOICE</td>
<td>No efficacy</td>
<td>29%</td>
<td>“ ”</td>
</tr>
</tbody>
</table>
PrEP Concerns

- **Risk Compensation**: not seen in trials
- **Renal insufficiency**: rare, reversible
  - but pts had to have normal function for trials
- **Bone demineralization**: statistically significant, not clinically significant at 18 months, needs f/u
- **Transmission of resistance**
  - Only in pts started on PrEP with acute HIV
  - All but 1 case 184V (XTC R, less fit virus)

*But it is early, and ongoing monitoring needed*
Relative risk reduction in acquiring HIV infection (compared with placebo) based on plasma TFV concentrations (Partners PrEP)
Improving Adherence Results in Exceedingly High Levels of Protection

• Partners PrEP adherence sub-study

• 1,147 couples in Uganda: those whose three-month pill use dropped below 80% received enhanced counseling which included problem-solving

• Sub-study also included unannounced home visits; pill use measurement by MEMSCAP

• At the end of the study, 14 participants became HIV-infected, none randomized to TDF/FTC

(Haberer, PLoS Medicine, 2013)
Correlates of Drug Detectability in iPrEx

- 179 samples from 7 sites were evaluated after Wk 24 visit

- Overall detection rate
  - TFV-DP: 50%
  - FTC-TP: 62%

<table>
<thead>
<tr>
<th>Parameter</th>
<th>n</th>
<th>Drug Detected, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>US vs non-US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>34</td>
<td>97</td>
</tr>
<tr>
<td>Non-US</td>
<td>145</td>
<td>50</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 25 yrs</td>
<td>101</td>
<td>73</td>
</tr>
<tr>
<td>&lt; 25 yrs</td>
<td>78</td>
<td>44</td>
</tr>
<tr>
<td>Recent reported sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>URAI</td>
<td>49</td>
<td>76</td>
</tr>
<tr>
<td>Sex, not URAI</td>
<td>107</td>
<td>59</td>
</tr>
<tr>
<td>No sex</td>
<td>23</td>
<td>35</td>
</tr>
</tbody>
</table>

## Risk Factors For HIV Seroconversion In The Gap Between Randomized And OLE

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>HR (95% CI)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condomless receptive anal intercourse</td>
<td>2.1 (1.1 to 3.8)</td>
<td>0.002</td>
</tr>
<tr>
<td>Age (each year older)</td>
<td>0.93 (0.90 to 0.98)</td>
<td>0.02</td>
</tr>
<tr>
<td>HSV infection</td>
<td>2.7 (1.6 to 4.7)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Depressed (CESD&gt;16)</td>
<td>1.5 (.9 to 2.4)</td>
<td>0.1</td>
</tr>
</tbody>
</table>
**IPrEX Open Label Study – Fenway Health**

- **93 Participants (51 from iPrEX and 42 from CDC PrEP)** about ½ of those in the initial studies

- **90 MSM, 3 transgender women**

- **22.6% African-American; 9.7% multiracial; 2.3% Latino**

- **Drug detection: 94.7% of samples tested**

- **Reasons for non-adherence:**
  - Side effects (flatulence)
  - Contraindicated with diabetes medication
  - Traveling
  - Intermittent adherence (drug detected next visit)
# Key scientific and implementation science questions for PrEP

<table>
<thead>
<tr>
<th>Topic</th>
<th>Key questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority populations</td>
<td>Who should be prioritized for PrEP? What are key PrEP messages, and how best to disseminate?</td>
</tr>
<tr>
<td>Uptake</td>
<td>What is level of interest in PrEP? Who will want PrEP? How to increase uptake in those who need it most?</td>
</tr>
<tr>
<td>Adherence</td>
<td>How will PrEP be used? (adherence, persistence) How to start/stop PrEP safely? What are effective strategies to increase PrEP adherence?</td>
</tr>
<tr>
<td>Sexual behavior</td>
<td>How will sexual practices change while taking PrEP? What are best approaches to minimize risk compensation?</td>
</tr>
<tr>
<td>Safety</td>
<td>What is long term safety of PrEP? (renal, bone) What is optimal HIV testing strategy and frequency?</td>
</tr>
<tr>
<td>Delivery</td>
<td>Where are PrEP delivery systems best located? How best to support PrEP providers?</td>
</tr>
<tr>
<td>Impact</td>
<td>How can cost-effectiveness of PrEP be maximized? How should PrEP be prioritized with other prevention strategies?</td>
</tr>
</tbody>
</table>

Baeten, Haberer, Liu et al JAIDS 2013
PrEP Cascade
(D. Smith, CDC and Al Liu, SFDPH)

Patients
1. At risk for HIV infection
2. Identified as PrEP candidate
3. Interested in PrEP
4. Linked to PrEP program
5. Initiated PrEP
6. Retained in PrEP program
7. Achieve and maintain medication adherence

Providers
1. Providing health care to high risk populations
2. Educated about PrEP
3. Willing to provide PrEP
<table>
<thead>
<tr>
<th>Trial/project</th>
<th>Sponsor/funder</th>
<th>Type/Category</th>
<th>Location</th>
<th>Population</th>
<th>Design/Key questions</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partners Demonstration Project</td>
<td>Led by a team of scientists from Kenya, Uganda and the US; funded by NIH, USAID and BMGF</td>
<td>Demonstration Project</td>
<td>Kenya, Uganda</td>
<td>Serodiscordant couples</td>
<td>Evaluates HIV prevention preferences among approximately 1,000 HIV serodiscordant couples, adherence to PrEP and ART and interface of reproductive health priorities and ART-based prevention. Will implement PrEP as “bridge” to ART, providing PrEP to HIV-negative partner when HIV-positive partner is not yet on ART due to ineligibility based on country guidelines or personal decision.</td>
<td>All four sites open and enrolling as of August 2013; results expected in 2016.</td>
</tr>
<tr>
<td>LVCT and SWOP</td>
<td>Implemented by national partners in each country in collaboration with the World Health Organization, UNAIDS, O’Neill Institute of Geotechnology University, London School of Hygiene and Tropical Medicine, Imperial College London; funded by Bill &amp; Melinda Gates Foundation</td>
<td>Demonstration Project</td>
<td>Kenya</td>
<td>Young women, female sex workers and MSM</td>
<td>Aims to introduce PrEP into combination prevention interventions targeting young women, female sex workers and MSM. Formative research underway to assess consumer perceptions and identify potential barriers and opportunities related to introduction. Outcomes include criteria for PrEP indication among young women and a menu of interventions for target populations, including PrEP and feasible delivery options.</td>
<td>Formative research in planning phase; feasibility study report results likely in December 2013.</td>
</tr>
<tr>
<td>Nigerian National Agency for the Control of AIDS</td>
<td></td>
<td>Demonstration Project</td>
<td>Nigeria</td>
<td>Serodiscordant couples</td>
<td>Evaluates the effectiveness of various models for the delivery of PrEP and Tasp as part of a combination prevention strategy for 1,200 heterosexual, serodiscordant couples. Couples will be recruited from facilities that provide prevention of vertical transmission, ART and other services. Study sites include Plateau, Edo and Cross River State. Study findings will be used to inform the scale-up of PrEP and Tasp as part of a comprehensive national HIV-prevention package.</td>
<td>Formative discussions underway. No start date for demonstration project.</td>
</tr>
<tr>
<td>Wits Reproductive Health and HIV Institute</td>
<td></td>
<td>Demonstration Project</td>
<td>South Africa</td>
<td>Female sex workers</td>
<td>Aims to assess whether oral PrEP and Tasp can be rolled out within a combination prevention and care approach tailored to the needs of 605, both HIV-positive and negative, female sex workers age 18 and older. Study sites include Hillbrow and Waterval Boven.</td>
<td>Expected start date of February 2014, with expected completion September 2016.</td>
</tr>
<tr>
<td>Durbar (DMSC) and Ashodaya Samithi</td>
<td></td>
<td>Demonstration Project</td>
<td>India</td>
<td>Female and transgender sex workers</td>
<td>Aims to assess the potential introduction of PrEP among female and transgender sex workers. The project includes sex workers part of the Durbar Mahila Samanwaya Committee (DMSC), a brothel-based sex work project in Sonagachi, and also the Ashodaya Samithi project, a CBO for street-based sex workers based in Mysore.</td>
<td>Feasibility study underway from May to September 2013, with results expected in October 2013.</td>
</tr>
<tr>
<td>The Demo Project</td>
<td>National Institute of Allergy and Infectious Diseases of the NIH</td>
<td>Demonstration Project</td>
<td>US (Miami, Florida; San Francisco, California; and Washington, DC)</td>
<td>MSM and transgender women</td>
<td>Aims to enroll 300 HIV-negative MSM and transgender women at City Clinic, while a sister project in Miami will enroll 200 participants in a PrEP regimen. Whitman Walker Clinic in Washington, DC, will also be a site, aiming to enroll approximately 100 participants.</td>
<td>Started October 2012. Expected completion by August 2014.</td>
</tr>
<tr>
<td>East Bay Consortium/CRUSH (Connecting Resources for Urban Sexual Health)</td>
<td>California HIV/AIDS Research Program of the University of California</td>
<td>Demonstration Project</td>
<td>US (East Bay, California)</td>
<td>Young MSM of color</td>
<td>Aims to test and link young MSM of color to sexual health services; enhance and evaluate engagement and retention strategies for HIV-positive young MSM of color; and engage and retain HIV-negative young MSM of color in sexual health services, including PrEP.</td>
<td>Started in December 2012.</td>
</tr>
</tbody>
</table>
## PrEP Demo Projects in the US

<table>
<thead>
<tr>
<th>Study</th>
<th>Population (N)</th>
<th>Study design</th>
<th>Sites</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>iPrEx OLE (Open Label Extension)</td>
<td>300 MSM /trans women enrolled in iPrEx RCT</td>
<td>Open-label daily FTC/TDF for 72 weeks</td>
<td>San Francisco Boston Chicago</td>
<td>Full enrolled; results 2014</td>
</tr>
<tr>
<td><strong>Demo Project</strong></td>
<td>600 MSM/trans women</td>
<td>Open-label daily FTC/TDF for 48 weeks</td>
<td>San Francisco Miami Washington DC</td>
<td>Enrollment Q3 2013, results 2015</td>
</tr>
<tr>
<td>CCTG 595</td>
<td>700 MSM/trans women</td>
<td>Open-label daily FTC/TDF for 48 weeks; Randomized to SMS support vs. SOC</td>
<td>San Diego Long Beach, LA Torrance</td>
<td>Enrollment Q2 2013, results 2016</td>
</tr>
<tr>
<td>PATH-PrEP</td>
<td>375 MSM/trans women</td>
<td>Open-label daily FTC/TDF for 48 weeks for high risk ; PEP for low risk</td>
<td>Los Angeles</td>
<td>Enrollment April 2013, results 2017</td>
</tr>
<tr>
<td>CRUSH</td>
<td>150 young MSM of color, high risk women</td>
<td>Open-label daily FTC/TDF</td>
<td>Oakland</td>
<td>Pilot phase: Q1 2013; expanded phase: Q4 2013</td>
</tr>
<tr>
<td>ATN 110 and 113</td>
<td>300 young MSM age 15-22</td>
<td>Open-label daily FTC/TDF for 48 weeks</td>
<td>All 14 ATN sites in US</td>
<td>Enrollment Dec 12, results Q4 2014</td>
</tr>
<tr>
<td>HPTN 073</td>
<td>225 Black MSM</td>
<td>Open-label daily FTC/TDF for 48 weeks</td>
<td>Washington DC, LA, Chapel Hill</td>
<td>Enrollment June 2013, results 2017</td>
</tr>
<tr>
<td>SPARK</td>
<td>~300 MSM and trans women</td>
<td>Open-label daily FTC/TDF; will evaluate PrEP messages and SMS</td>
<td>New York</td>
<td>Enrollment Q4 2013</td>
</tr>
</tbody>
</table>
Strategies to improve PrEP delivery and adherence

New PrEP drugs and dosing strategies

Rectal Microbicides: MTN-017 (TFV rectal gel)

Intra-vaginal rings: ASPIRE (Dapivirine)

Injectable PrEP: HPTN 076 (TMC278LA)

Novel adherence strategies

Alternative delivery systems and formulations

The Future NEXT EXIT
Regression analysis in iPrEx: 90% reduction in HIV acquisition when TFV-DP > 16 fmol/10^6 cells

Predicted risk reduction:
- 76% with 2 pills / week
- 96% with 4 pills / week
- 99% with 7 pills / week

Anderson et al, Science Translational Medicine 2012 4:151ra125

* Visit when HIV was first discovered
Daily Truvada 1 tablet/d
Regardless of sexual activity
(n = 180)

Time driven Truvada: 1 tablet 2 days/week
+ 1 post-exposure dose within 2 hours after sex
(n = 180)

Event driven Truvada: 1 tablet prior to sex
+ 1 post-exposure dose within 2 hours after sex
(n = 180)

Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral PrEP with TDF/FTC

6-week lead-in period
1 pill/week DOT before randomization

High risk women and MSM
(New York, Bangkok, Cape Town)

Primary Objective: Is intermittent vs. daily dosing associated with equivalent coverage of sex events, lower number of pills used and decreased side effects

Wk 24 primary endpoint

Primary Objective: Is intermittent vs. daily dosing associated with equivalent coverage of sex events, lower number of pills used and decreased side effects
Effectiveness of “on demand” PrEP
Randomized placebo-controlled trial

- High risk MSM
- Condomless anal sex with ≥ 2 partners

Counseling, testing for STI, condoms, vaccination, PEP
Primary endpoint: HIV infection, 64 events expected
Incidence of HIV-infection: 3%PY, 50% efficacy, ~ 2000 pts
MVC 150 Participants
- 100 MSM
- 50 Women

MVC + FTC 150 Participants
- 100 MSM
- 50 Women

MVC + TDF 150 Participants
- 100 MSM
- 50 Women

FTC + TDF 150 Participants
- 100 MSM
- 50 Women

HIV Prevention Trials Network
NEXT PrEP
Partners Demonstration Project: optimizing PrEP & ART for prevention

Recruit higher-risk HIV-1 serodiscordant couples

Offer/refer for ART for HIV-1+ partners according to current national guidelines

Accepts ART
- Offer PrEP for 6 months to HIV-1- partner
- Continue to counsel HIV-1+ partner on ART

Declines ART
- Offer PrEP to HIV-1- partner

Not yet eligible for ART
- Offer PrEP to HIV-1- partner
- Follow HIV-1+ partner and refer for ART when eligible

ART Prioritization

Timeline: late 2012 to mid 2016

PrEP as bridge to ART
Partners Demonstration Project: Status

- Enrollment has been ongoing since November 2012 – 4\textsuperscript{th} site (Kabwohe, Uganda) started enrolling in August 2013
  - 313 couples enrolled as of Sep 2013
- High interest and uptake of PrEP at enrollment: >90% of participants
- ART willingness is high among eligible participants at enrollment: >70% accept a referral or onsite prescription
- Retention rates: ~90% for HIV uninfected partners, ~88% for HIV infected partners
Adolescent PrEP

- ATN 082 enrolled 68 young MSM
- 70% agreed to take PrEP
- Of PrEP users, blood levels indicate about 50% adherence, comparable to self-report
- Lots of psychosocial issues reported
- ATN 110 and 113: open label TDF-FTC plus either group (Many Men, Many Voices) or individual intervention (Personal Cognitive Counseling)
- ATN 110: 18-12 yo; ATN 113: 15-17 yo
Are you willing to take part in research that aims to reduce your risk of HIV?
Participation is straightforward and won’t take much of your time.

Volunteers

Why take part?

The study will give us more information about how PrEP could be used to prevent new HIV infections amongst gay men.

By taking part, you could reduce your own risk of catching HIV.

Our team will help and support you to be healthy.

You can take part in the study if you:

- Are HIV negative
- Are 18 or older
- Have had anal sex without a condom in the last three months.
- Are likely to do this again in the next three months.
- Can visit the clinic for blood tests every three months.
PROUD Pilot

MSM reporting UAI
Willing to take a pill now or in 12M

Randomize 500 HIV negative eligible MSM
(exclude if on treatment for hepB)

Risk reduction includes
Truvada **NOW**

Risk reduction includes
Truvada **in 12M**

Follow **3 monthly** for up to 24 months (+1m after start truvada)
Online **daily** diary and **monthly** questionnaires
The SFDPH Demo Project

• NIAID-funded PrEP Demonstration Project in 600 MSM and transgender women
  – STD clinics in SF, Miami; CHC in DC

• Key objectives:
  – Assess PrEP uptake, adherence, resistance, and sexual behaviors in real-world setting
  – Determine staff and space needed for PrEP delivery

• Study procedures:
  – Provide TDF/FTC PrEP for 48 weeks
  – Study visits at 1 month, then quarterly
  – Safety monitoring (HIV, Cr) at each visit
  – Integrated risk reduction and adherence counseling
SF Demo: Integrated Counseling (Liu et al)

- Education about pill use
- People who use PrEP more consistently have higher levels of protection against HIV
- Potential side-effects
  - Bloating, soft/more frequent stools, nausea
- Missed Doses
- Developing a routine
- Discussing PrEP with others
- Stopping and restarting PrEP
Some *preliminary* impressions (Al Liu)...

Social benefits
- Decreased anxiety
- Increased communication/disclosure
- Increased intimacy / trust
- Increased sense of community / self-efficacy
- Increased sexual pleasure

Social harms
- Stigma – HIV / risky behavior
- Negative health provider encounters
- Anxiety about accessing PrEP after Demo Project
Social Cognitive Model

- Pleasure reduction
- Disease prevention
- Social Models
- Self efficacy
- Safer Sex Adherence

Depression, anxiety, mental health problems, substance use

Wulfert, Safren, et al., 1999; Journal of Applied Social Psychology
Project PrEPare (Fenway)

• Modeled after “Life-Steps,” (Safren et al) ART adherence intervention
• Modular intervention: 4 weekly visits with nurse and 2 booster sessions.
• Intervention content:
  • CBT-oriented adherence problem-solving
  • Brief motivational interviewing
  • Identification of barriers and solutions
  • Sexual risk-reduction strategies
Optional modules:
• Mental health and substance use issues
Adherence to PrEP was measured daily via Wisepill, and sexual risk taking was assessed by text messages (Lester, 2010)
All participants will receive “Opt-in” adherence challenges discussion

Adherence assessed by:

- 4-day participant recall/pill count
- Real-time serum levels of TFV/FTC
- DBS for intra-erythrocytic TFV levels

If serum TFV < 10 ng/mL, Next-Step Counseling Intervention (NSC)

Repeat TFV levels <10 ng/mL, “PrEP-STEP” program
Diffusion of Innovations
(Everett Rogers, 1962)
Innovation, Communication Channels, Time, Social System
Uptake of ZDV for perinatal prevention
(in 18 states with HIV surveillance)

Source: Lindegren et al., JAMA 1999; 282-531-38
PrEP Attitudes and Uptake

- Manhunt survey pre/post iPrEX
  - 4,825 MSM: 46 states and 5 Canadian provinces
  - Less than 20% heard of PrEP
  - Less than 1% had used PrEP
  - Majority were interested, depending.....

- Massachusetts MD survey post-CAPRISA
  - Most had heard of CAPRISA 004
  - Some knew that PrEP studies were underway
  - Many concerns about risk compensation, resistance, cost

Krakower et al, PLoS ONE, 2012; White et al, AIDS Pt Care and STDs, 2012
How to increase appropriate uptake of PrEP?

Developing video testimonials from PrEP users

Project Inform launches new educational video series on PrEP!

- Making decisions to take PrEP with your doctor.
- Figuring out how PrEP fits into your life.

• Brief video testimonials developed regarding PrEP users’ decisions and motivations to take PrEP and experiences taking PrEP

• Also: www.myprepexperience.blogspot.com  AIDS Foundation of Chicago
PrEP Use in the US, 2013
(Mera et al, ICAAC, 2013)

- Pharmacy record review (55% of US pharmacies)
- 1,774 pts on PrEP between 1/11 and 3/13
- 53% in 1st half of 2013: increase utilization?
- Median age: 37 y.o. 13.6% <25 y.o.
- Women 47.7% of users
- 49 states; 700 cities; largest N in the South
- Only 37% of PrEP providers also prescribed HAART
- Only 12% of prescribers were ID docs
- Did not capture those in trials (more MSM)
PrEP Among MSM in Spanish and Portuguese Speaking Countries (Mimiaga et al)

- Design: An anonymous, online survey of members of a social networking site for MSM

- Sample: An email in Spanish or Portuguese with a link to the survey was sent to nearly 643,000 active members living in one of the Spanish- and Portuguese-speaking countries/territories in Latin America/Caribbean, or in Spain or Portugal
  - 246,620 emails were opened and 56,584 clicked on the link
  - 37,264 consented (66%) and 36,447 (64%) initiated the survey
  - Excluded:
    1. individuals who responded that they did not currently live in the included countries/territories
    2. individuals who reported being HIV-infected
  - The final sample was 33,101.
Current country of residence by awareness of PrEP, prior use of PrEP and interest in participating in a PrEP trial

<table>
<thead>
<tr>
<th>Country</th>
<th>Aware of PrEP (11.2%)</th>
<th>Prior Use of PrEP (0.9%)</th>
<th>Interest in PrEP Trial (69.4%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
<td>8.8</td>
<td>0.8</td>
<td>53.8</td>
</tr>
<tr>
<td>Portugal</td>
<td>10.2</td>
<td>0.6</td>
<td>52.3</td>
</tr>
<tr>
<td>Argentina</td>
<td>9.8</td>
<td>0.9</td>
<td>59.5</td>
</tr>
<tr>
<td>Brazil</td>
<td>19.3</td>
<td>0.8</td>
<td>62.0</td>
</tr>
<tr>
<td>Chile</td>
<td>8.3</td>
<td>0.8</td>
<td>72.4</td>
</tr>
<tr>
<td>Colombia</td>
<td>8.1</td>
<td>1.1</td>
<td>76.5</td>
</tr>
<tr>
<td>Mexico</td>
<td>10.5</td>
<td>1.0</td>
<td>79.9</td>
</tr>
<tr>
<td>Peru</td>
<td>16.5</td>
<td>0.3</td>
<td>79.2</td>
</tr>
<tr>
<td>Venezuela</td>
<td>9.1</td>
<td>0.9</td>
<td>70.8</td>
</tr>
</tbody>
</table>

p-value <0.0001  0.302  <0.0001
<table>
<thead>
<tr>
<th>PrEP Among MSM 2013: Limited Awareness and Use, Potential Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>• NYC MSM accessing online dating sites: 38% knew about PrEP; 1.5% reported use. (Rucinski)</td>
</tr>
<tr>
<td>• Young Chicago MSM (16 – 20 y.o) recruited by RDS, rare use, interest related to perceived risk and anticipated side-effects. (Mustanski)</td>
</tr>
<tr>
<td>• Australian MSM recruited online: little experience, favorable attitudes; less divisive than TaSP between HIV (+) and (−) MSM (Holt)</td>
</tr>
</tbody>
</table>

AIDS and Behavior, 2013
| Knowledge and Use of PrEP  
(Controlling the Epidemic with Antiretrovirals, London, 2013) |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Italian MSM (Corbelli, #8)</td>
</tr>
<tr>
<td>• British Nurses (Evans, #15)</td>
</tr>
<tr>
<td>• Kenyan Youth (Kurth, #17)</td>
</tr>
<tr>
<td>• Drug-using Cis- and Transgender US Women (Forbes, #19)</td>
</tr>
<tr>
<td>• Canadian MSM (Kain, #22)</td>
</tr>
<tr>
<td>• Italian PEP Users (Puro, #32)</td>
</tr>
<tr>
<td>• Vietnamese MSM (Colby, #49)</td>
</tr>
<tr>
<td>• US African and Caribbean Immigrants (Kwakwa, #52)</td>
</tr>
<tr>
<td>• African-Americans (Kwakwa, #53)</td>
</tr>
<tr>
<td>• IDU (Eseudero, #63)</td>
</tr>
</tbody>
</table>
Non Trial PrEP Use at Fenway Health

Dates of Initiation (N=50)
To implement PrEP successfully, it will be essential to engage practicing clinicians.

Review

What Primary Care Providers Need to Know About Preexposure Prophylaxis for HIV Prevention
A Narrative Review
Douglas Krakower, MD, and Kenneth H. Mayer, MD

As HIV prevalence climbs globally, including more than 50,000 new infections per year in the United States, we need more effective HIV prevention strategies. The use of antiretrovirals for preexposure prophylaxis (PrEP) among high-risk persons without HIV is emerging as one such strategy. Randomized, controlled trials have demonstrated that once-daily oral PrEP decreased HIV incidence among at-risk men who have sex with men and African heterosexuals, including serodiscordant couples. An additional randomized, controlled trial of a topical perineal antiretroviral microbicide gel decreased HIV incidence among at-risk heterosexual South African women. Two other studies in African women did not demonstrate the efficacy of oral or topical PrEP, raising concerns about adherence patterns and efficacy in this population.

The U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee reviewed these studies and additional data in May 2012 and voted to advise the approval of oral tenofovir-emtricitabine for PrEP in high-risk populations. On 16 July 2012, the FDA recommended that this combination medication be approved for use as PrEP in high-risk persons without HIV. Patients may seek PrEP from their primary care providers, and those receiving PrEP require monitoring. Thus, primary care providers should become familiar with PrEP. This review outlines current knowledge about PrEP as it pertains to primary care, including identifying persons likely to benefit from PrEP; counseling to maximize adherence and reduce potential increases in risky behavior; and monitoring for potential drug toxicities, HIV acquisition, and antiretroviral drug resistance. Issues related to cost and insurance coverage are also discussed. Recent data suggest that PrEP, combined with other prevention strategies, holds promise in helping to curtail the HIV epidemic.

Annals of Internal Medicine

For author affiliations, see end of text.
This article was published on www.annals.org on 22 July 2012.
HIV providers’ perceived facilitators and barriers to prescribing PrEP

• Qualitative study of Boston HIV providers over past year
• 6 Focus groups (4 hospital-based clinics, 2 community health centers)
• Semi-structured discussion guide
• Perceptions about prescribing PrEP
• Inductive approach to data analysis

(Krakower, NIMH-IAPAC, 2013)
Well you know I think the PrEP data regardless of the gender study that was performed, I think really show that PrEP works, when it’s used correctly.
–Male, Hospital-based

I would prescribe it. It obviously works.
-Male, Hospital-based
Practical issue number one is that the people who are going to be prescribing these drugs in theory, who are going to be in the best position, are going to be primary care providers with little or no HIV experience.

– Male, Hospital-based

I think that the idea of adding to what I just did this morning and adding a discussion with my patients about what is their likelihood of having sexual encounters with patients who are HIV-infected, and then on top of that trying to prescribe and get approved medication like Truvada or some other pre-exposure prophylaxis... I just can’t imagine it working in the hands of a primary care doctor.

– Female, Hospital-based
Emerging Infections Network

- 1290 ID docs, 44.4% response (6/15/13 – 7/7/13)
- 74% supported concept of PrEP
- 9% have provided PrEP (N=51)
- 43% would provide PrEP if they had the right opportunity
- 14% have not provided PrEP because of:
  - Concerns about compliance and future resistance (77%)
  - Concerns about cost/payor issues (57%)
  - Concerns about toxicities (53%)
  - Insufficient evidence of “real world” efficacy (53%)
PrEP 2013

• Proof of Concept established
• Scientific and implementation science questions remain
• Next steps: Develop and test interventions to optimize PrEP delivery
  - Prioritize PrEP to maximize population level impact
  - Increase appropriate uptake
  - Develop tools to support PrEP users (adherence, risk reduction)
  - Develop tools to support PrEP providers (identifying PrEP candidates, providing adherence / risk reduction support, decision making on starting/stopping PrEP)
  - Use technology to enhance scalability and sustainability

But PrEP drugs, dosing intervals and delivery systems may change
Combination Antiretroviral Prevention

Interventions to Increase Testing

Test

HIV Negative

Risk Assessment

PrEP, Adherence Counseling

HIV Positive

Positive Prevention

Linkage To Care

Enroll in Care

ART Initiation

Treat

Adherence to ART

Maintain Viral Suppression

Decrease in HIV Transmission

Address concomitant concerns, e.g. depression, substance use, relationship dynamics
Thank You

Fenway Clinical, Epidemiological and Behavioral Research Teams
Fenway Medical Department
Slim and Quarraisha Abdool Karim
Jared Baeten
Katie Biello
Susan Buchbinder
Connie Celum
Robert Grant
Sharon Hillier
Doug Krakower
Albert Liu
Sheena McCormack
Matthew Mimiaga
Jean-Michel Molina
David Novak
Jim Rooney
Josh Rosenberger
Steve Safren
Dawn Smith
Roger Tatoud
NIAID, NIMH, NIDA, NICHD, CDC, HRSA, Mass DPH, Gilead
www.thefenwayinstitute.org